Immunovant price target lowered to $38 from $45 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...
Immunovant price target lowered to $44 from $46 at Guggenheim
Guggenheim lowered the firm’s price target on Immunovant (IMVT) to $44 from $46 and keeps a Buy rating on the shares after having hosted ...
Hosted on MSN14d
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025
In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks. A lot is happening in the market, especially within the growth sectors.
Yahoo Finance15d
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025
We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks. A lot is ...
Insider Monkey15d
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025
Immunovant, Inc. (NASDAQ:IMVT) is a biotechnology company that ranks eighth on our list of stocks expected to double in 2025. IMVT has a focus on developing advanced treatments for patients with ...
ETF Daily News16d
Immunovant (NASDAQ:IMVT) Hits New 1-Year Low on Insider Selling
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) reached a new 52-week low on Monday after an insider sold shares in the company.The company traded as low as $22.35 and last traded at $22.38 ...
Investing19d
Immunovant registers shares for selling stockholders
Immunovant, Inc. (NASDAQ:IMVT), a biopharmaceutical company specializing in biological products currently valued at $3.4 billion, has registered shares for resale by certain selling stockholders, ...